Kevin Stankiewicz

Kevin Stankiewicz is a reporter for the CNBC Investing Club. Prior to joining CNBC in August 2019, he worked as a staff reporter for The Columbus Dispatch in Ohio. His work also has appeared in the Pittsburgh Post-Gazette and The Washington Post. He studied journalism and geography at Ohio State University.

80%

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

88%

Examples:

  • The S&P 500 notched a record close Friday for the first time in more than two years — and over that time, no Club stock has performed better than Eli Lilly.

Conflicts of Interest

75%

Examples:

  • Eli Lilly is on track for a new high Thursday after unveiling a service aimed at making it easier for patients to access weight-loss drugs.
  • The S&P 500 notched a record close Friday for the first time in more than two years — and over that time, no Club stock has performed better than Eli Lilly.

Contradictions

75%

Examples:

  • The title implies that Eli Lilly has launched a new service for weight-loss drugs when in fact it's just making them more accessible to patients.
  • The title implies that the S&P 500 has set a new record high when it hasn't.

Deceptions

75%

Examples:

  • The title implies that Eli Lilly has launched a new service for weight-loss drugs when in fact it's just making them more accessible to patients.
  • The title implies that the S&P 500 has set a new record high when it hasn't.

Recent Articles

Tech Sector Drives Bull Run in Stock Market as Federal Reserve Considers Rate Cuts

Tech Sector Drives Bull Run in Stock Market as Federal Reserve Considers Rate Cuts

Broke On: Wednesday, 31 January 2024 The stock market is experiencing a bull run, driven by the tech sector. Despite concerns about inflation and interest rates, investors are optimistic that the Federal Reserve will cut rates to spur economic growth.
Eli Lilly Launches New Service for Telehealth Prescriptions of Weight Loss Drugs

Eli Lilly Launches New Service for Telehealth Prescriptions of Weight Loss Drugs

Broke On: Friday, 05 January 2024 Eli Lilly has launched an online service called LillyDirect The platform allows patients to receive telehealth prescriptions and direct home delivery of certain medications for obesity, diabetes and migraines This marks a shift in the drug supply chain by a pharmaceutical company into the digital health-care space Some analysts view this move as an opportunity for Lilly to gain market share in weight loss solutions Others are concerned about its potential impact on traditional players like WeightWatchers and other companies that provide online access to prescription weight-loss drugs.